| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms |
109 |
| Current Challenges and Opportunities in Treating Glioblastoma |
100 |
| Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach |
82 |
| A Practical Review of Proteasome Pharmacology |
56 |
| Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure |
56 |
| Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology |
56 |
| WNT Signaling in Cardiac and Vascular Disease |
46 |
| Trace Amines and Their Receptors |
45 |
| Etiology and Pharmacology of Neuropathic Pain |
45 |
| Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions |
41 |
| REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics |
39 |
| Biased Receptor Signaling in Drug Discovery |
36 |
| Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption |
35 |
| Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions |
33 |
| Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery |
31 |
| International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
30 |
| Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies |
29 |
| The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases |
26 |
| International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans |
25 |
| Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases |
23 |
| Anti-Obesity Therapy: from Rainbow Pills to Polyagonists |
23 |
| Harnessing Ion-Binding Sites for GPCR Pharmacology |
21 |
| International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin(1)) and GPR1 (Chemerin(2)) Nomenclature, Pharmacology, and Function |
18 |
| Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products |
16 |
| Core Outcome Measures in Preclinical Assessment of Candidate Analgesics |
14 |
| G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus |
13 |
| Biomarkers for In Vivo Assessment of Transporter Function |
12 |
| Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development |
12 |
| Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health |
12 |
| International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets |
11 |
| The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation |
10 |
| 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface |
10 |
| RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer |
9 |
| International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand |
9 |
| Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progress, and Challenges |
8 |
| Mechanisms and Drug Development in Atrial Fibrillation |
8 |
| Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs |
8 |
| Cell Volume-Activated and Volume-Correlated Anion Channels in Mammalian Cells: Their Biophysical, Molecular, and Pharmacological Properties |
8 |
| Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease |
6 |
| Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology |
4 |
| Challenges and Opportunities for Childhood Cancer Drug Development |
3 |
| Beyond the Ligand: Extracellular and Transcellular G Protein-Coupled Receptor Complexes in Physiology and Pharmacology |
3 |
| Druggable Transcriptional Networks in the Human Neurogenic Epigenome |
2 |
| A Pharmacological Perspective on the Study of Taste |
2 |
| Dose-Response-Time Data Analysis: An Underexploited Trinity |
2 |
| Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose |
1 |
| Role of Voltage-Gated Sodium Channels in the Mechanism of Ether-Induced Unconsciousness |
0 |
